SS Genotype and SSRI Treatment for Anxiety

Clinical Implications of SS Genotype

• The American College of Medical Genetics recommends that the SS genotype of the serotonin transporter promoter polymorphism (5-HTTLPR) is associated with slower symptom improvement and potentially reduced response to SSRIs, but current evidence does not support routine genetic testing to guide initial SSRI selection for anxiety treatment 1, 2, 3
• The EGAPP Working Group found insufficient evidence to recommend routine CYP450 or serotonin transporter genetic testing for patients starting SSRI treatment, rating most supporting studies as quality level 3-4 out of 5 1, 4
• Standard first-line SSRIs (sertraline, escitalopram, fluoxetine) remain appropriate initial choices regardless of genotype, and the evidence does not support withholding SSRIs or selecting alternative medication classes in SS patients 1, 2, 3
• For patients with known SS genotype, implement closer early monitoring, assessing response at 2-3 weeks rather than waiting the standard 4-6 weeks, as SS patients may require longer to show improvement 1
• The SS genotype information becomes more clinically relevant in specific scenarios, such as after initial treatment failure or intolerable side effects with one or more SSRIs 2, 3
• When choosing between SSRIs, fluoxetine may be preferable as it has less CYP2C19-dependent metabolism compared to citalopram or escitalopram 5